Citius Oncology Reports $24.8 Million Net Loss and No Revenue in Annual Filing

Citius Oncology, Inc. has reported significant financial developments in its annual Form 10-K filing for the fiscal year ending September 30, 2025. The company, which focuses on developing targeted oncology therapies, particularly its lead product LYMPHIR (denileukin diftitox), recorded no revenue during the fiscal year. The net loss for the year was approximately $24.8 million, an increase from a net loss of $21.1 million in the previous year. This increase in losses is attributed to higher research and development expenses, which rose to $6.4 million from $4.9 million, and general and administrative expenses, which increased to $8.8 million from $8.1 million.

Citius Oncology's operational strategy has seen notable changes, particularly following the FDA approval of LYMPHIR in August 2024 and its subsequent launch in December 2025. The company has established a targeted oncology sales force and entered into distribution agreements with major pharmaceutical wholesalers to facilitate the product's market entry. The company is also actively engaging with regional distribution partners to expand its reach in Europe, South America, and the Middle East. As of September 30, 2025, Citius Oncology had approximately $3.9 million in cash and a negative working capital of about $21.9 million, indicating a pressing need for additional funding to support ongoing operations and commercialization efforts.

The company has outlined its financial obligations, including milestone payments totaling $27.5 million to Dr. Reddy’s upon FDA approval of LYMPHIR, with a remaining balance of $19.75 million as of the reporting date. Additionally, Citius Oncology is required to make payments to Eisai totaling $5.9 million for milestone achievements and up to $22 million related to net product sales thresholds. The company has indicated that it will continue to rely on funding from Citius Pharma, its majority shareholder, as well as potential equity financing to meet these obligations and support its operations beyond March 2026.

Looking ahead, Citius Oncology's management has expressed optimism regarding the market potential for LYMPHIR, estimating an addressable market exceeding $400 million. However, the company acknowledges the inherent risks associated with the commercialization of LYMPHIR, including competition from established therapies, the need for effective marketing and distribution strategies, and the necessity of securing adequate reimbursement from healthcare payers. The company’s future performance will largely depend on its ability to successfully launch LYMPHIR and generate substantial revenue, as well as its capacity to navigate the complexities of the biopharmaceutical landscape.